PerpEquities

Equity · Healthcare

Oscar Health, Inc. (OSCR) perpetual futures

OSCR perpetual futures on 3 crypto exchanges – live perp price vs the stock, funding rate, open interest and where to trade OSCRUSDT.

Oscar Health, Inc. is a US health insurer offering individual, family, small business, and Medicare Advantage plans, plus its +Oscar technology platform and reinsurance solutions.

$32.54+4.8%NYSE closed
Open in terminal

Price chart

 

Use the left and right arrow keys to inspect points on the chart.

Collecting venue price data...
venue perp mark · BingX (OSCR-USDT)
Auto: highest-volume live perp venueOpen in TradingView

Trading data

Perpetual market activity

3/3 live markets
Venues
3
Live markets
3/3
24h volume
$49.8KCoverage: 2/3 marketsExchange-reported volume: $1.3M
Open interest
$85.8K
Best liquidity
$4.8K
LBank
Tightest spread
+40.0 bps
OKX
Highest volume
$30.9K
LBank
Settlement mix
USDT · 3/3
Perp/spot vol.
0.00x
Spot volume $126.9M
OI / float
0.00%
Float $8.1B
Spot performance
1D+3.48%
5D+4.00%
1M-4.06%
6M+142.48%
YTD+115.31%
1Y+38.68%

Venue matrix

3 markets

Some venue links are sponsored. We may receive a commission, and eligible users may occasionally receive trading-fee discounts, at no additional cost to you.

Trade
LBankTradeOSCR/USDTTrading$32.540.0% APR
0.000% every 8h
+144.5 bps$4.8K$30.9K$17.4KUSDT50x
OKXTradeOSCR/USDTTrading$32.520.0% APR
0.000% every 8h
+40.0 bps$3.1K$18.8K$65.3KUSDT10x
BingXTradeOSCR-USDTTrading$32.62+5.5% APR
+0.00500% every 8h
+42.9 bps$3.4K$1.2M⚠$3.1KUSDT-

Unverified volume: implausibly high against open interest, a typical sign of wash trading. These venues are listed last.

Tradability

Execution quality

Entry cost and depth per venue at $1k–$100k

No sufficient depth · 0 of 3 venues absorb $10k

Too thin: BingX, OKX

No fresh book data: LBank

Taker execution estimate incl. approx. fees - maker fills are not guaranteed.

Best venues for this underlying

Best liquidity

OSCR

Tightest spread

OSCR

Highest volume

OSCR

Funding history

Stored venue snapshots by market

Company data

Company fundamentals

Updated 1h ago
Market cap
$8.4B
Updated 1h ago
Revenue
$15.3B
Trailing 12 months
Revenue growth
+59%
Next fiscal year
Profit margin
+3.6%
P/E
19.0
Peer P/E 5.5
Free cash flow
$4.3B
Trailing 12 months
More metrics
Net income
$550.7M
Trailing 12 months
P/S
0.5
Peer P/E
5.5
Similar listed perps
Revenue estimate
$18.7B
Next fiscal year
Earnings
2026-11-09
Revenue est. $4.7B · Updated 1h ago
Dividend
-

Fundamental detail

Annual + quarterly
Latest revenue$11.7B
Net margin-3.8%
Free cash flow$1.1B
Net debt-$2.3B
2020$589.6M
2021$1.9B
2022$4.1B
2023$5.9B
2024$9.2B
2025$11.7B
PeriodRevenueGrowthNet incomeFCF
2020$589.6M+6%-$406.8M$208.7M
2021$1.9B+226%-$572.6M-$207.6M
2022$4.1B+115%-$606.3M$351.3M
2023$5.9B+42%-$270.7M-$297.7M
2024$9.2B+57%$25.4M$950.3M
2025$11.7B+28%-$443.2M$1.1B
PeriodGross marginOperating marginNet marginROEROA
2020+100.0%-68.8%-69.0%+31.4%-17.9%
2021+100.0%-29.7%-29.8%-41.3%-17.2%
2022+100.0%-14.8%-14.7%-68.1%-13.4%
2023+20.8%-4.0%-4.6%-33.7%-7.5%
2024+20.1%+0.6%+0.3%+2.5%+0.5%
2025+14.4%-3.4%-3.8%-45.3%-7.0%
PeriodCashDebtNet debtCurrent ratio
2020$826.3M$142.5M-$683.8M0.00
2021$1.1B$0-$1.1B1.71
2022$1.6B$298M-$1.3B1.40
2023$1.9B$298.8M-$1.6B-11.82
2024$1.5B$299.6M-$1.2B0.90
2025$2.8B$430.1M-$2.3B0.95
PeriodMarket capEnterprise valueP/SP/E
2020$8.3B$7.6B14.1-20.5
2021$1.4B$300.9M0.7-2.5
2022$522.7M-$737.9M0.1-0.9
2023$2B$456.6M0.3-7.5
2024$3.2B$2B0.4122.2
2025$3.8B$1.4B0.3-8.5
Q3 2024$2.4B
Q4 2024$2.4B
Q1 2025$3B
Q2 2025$2.9B
Q3 2025$3B
Q4 2025$2.8B
Q1 2026$4.6B
Q2 2026$4.9B
PeriodRevenueGrowthNet incomeFCF
Q3 2024$2.4B+68%-$54.6M-$507.7M
Q4 2024$2.4B+67%-$153.5M$340M
Q1 2025$3B+42%$275.3M$869.5M
Q2 2025$2.9B+29%-$228.4M$499.8M
Q3 2025$3B+23%-$137.5M-$973.7M
Q4 2025$2.8B+17%-$352.6M$662.8M
Q1 2026$4.6B+53%$679M$2.6B
Q2 2026$4.9B+70%$361.8M$2B
PeriodGross marginOperating marginNet marginROEROA
Q3 2024+100.0%-2.2%-2.3%-4.7%-1.2%
Q4 2024+13.7%-6.2%-6.4%-15.1%-3.2%
Q1 2025+25.8%+9.8%+9.0%+20.6%+4.7%
Q2 2025+10.9%-8.0%-8.0%-19.7%-3.6%
Q3 2025+13.4%-4.3%-4.6%-13.4%-2.4%
Q4 2025+6.6%-11.9%-12.6%-36.1%-5.6%
Q1 2026+30.5%+15.2%+14.6%+40.8%+7.3%
Q2 2026+100.0%+7.8%+7.4%+17.6%+3.2%
PeriodCashDebtNet debtCurrent ratio
Q3 2024$1.2B$299.4M-$906.8M0.80
Q4 2024$1.5B$299.6M-$1.2B0.82
Q1 2025$2.2B$299.7M-$1.9B0.91
Q2 2025$2.6B$299.9M-$2.3B0.89
Q3 2025$2.1B$686.3M-$1.5B1.10
Q4 2025$2.8B$430.1M-$2.3B1.10
Q1 2026$4.8B$430.9M-$4.4B1.09
Q2 2026$4.1B$431.6M-$3.6B1.08
PeriodMarket capEnterprise valueP/SP/E
Q3 2024$5.2B$4.2B2.1-24.1
Q4 2024$3.2B$2B1.4-5.4
Q1 2025$3.3B$1.4B1.13.0
Q2 2025$5.4B$3.1B1.9-6.0
Q3 2025$4.9B$3.4B1.6-8.9
Q4 2025$4.1B$1.7B1.5-2.9
Q1 2026$3.4B-$954.1M0.71.3
Q2 2026$8.6B$5B1.85.9

Refreshed 1h ago

Charts: revenue, profit, cash flow & valuation
Revenue$4.9BQ2 2026
$1.2B$2.4B$3.7B$4.9BQ3 2023: $1.4BQ4 2023: $1.4BQ1 2024: $2.1BQ2 2024: $2.2BQ3 2024: $2.4BQ4 2024: $2.4BQ1 2025: $3BQ2 2025: $2.9BQ3 2025: $3BQ4 2025: $2.8BQ1 2026: $4.6BQ2 2026: $4.9BQ3 2023Q2 2026
Net income$361.8MQ2 2026
-$94.7M$163.2M$421.1M$679MQ3 2023: -$65.4MQ4 2023: -$150MQ1 2024: $177.4MQ2 2024: $56.2MQ3 2024: -$54.6MQ4 2024: -$153.5MQ1 2025: $275.3MQ2 2025: -$228.4MQ3 2025: -$137.5MQ4 2025: -$352.6MQ1 2026: $679MQ2 2026: $361.8MQ3 2023Q2 2026
EBITDA$393.8MQ2 2026
-$81.8M$182.5M$446.8M$711.1MQ3 2023: -$49.5MQ4 2023: -$136.7MQ1 2024: $192.2MQ2 2024: $74.5MQ3 2024: -$39MQ4 2024: -$138.4MQ1 2025: $300.9MQ2 2025: -$220.7MQ3 2025: -$125.1MQ4 2025: -$346.1MQ1 2026: $711.1MQ2 2026: $393.8MQ3 2023Q2 2026
Free cash flow$2BQ2 2026
-$214.3M$727.2M$1.7B$2.6BQ3 2023: -$1.2BQ4 2023: $290.8MQ1 2024: $628.4MQ2 2024: $489.6MQ3 2024: -$507.7MQ4 2024: $340MQ1 2025: $869.5MQ2 2025: $499.8MQ3 2025: -$973.7MQ4 2025: $662.8MQ1 2026: $2.6BQ2 2026: $2BQ3 2023Q2 2026
EPS$1.1Q2 2026
-$0.41$0.41$1.24$2.07Q3 2023: -$0.29Q4 2023: -$0.66Q1 2024: $0.62Q2 2024: $0.18Q3 2024: -$0.22Q4 2024: -$0.62Q1 2025: $0.92Q2 2025: -$0.84Q3 2025: -$0.53Q4 2025: -$1.24Q1 2026: $2.07Q2 2026: $1.1Q3 2023Q2 2026
Cash / Debt$4.1BQ2 2026
$1.2B$2.4B$3.6B$4.8BQ3 2023 · Cash: $1.4BQ3 2023 · Debt: $298.6MQ4 2023 · Cash: $1.9BQ4 2023 · Debt: $298.8MQ1 2024 · Cash: $2.2BQ1 2024 · Debt: $299MQ2 2024 · Cash: $2.3BQ2 2024 · Debt: $299.2MQ3 2024 · Cash: $1.2BQ3 2024 · Debt: $299.4MQ4 2024 · Cash: $1.5BQ4 2024 · Debt: $299.6MQ1 2025 · Cash: $2.2BQ1 2025 · Debt: $299.7MQ2 2025 · Cash: $2.6BQ2 2025 · Debt: $299.9MQ3 2025 · Cash: $2.1BQ3 2025 · Debt: $686.3MQ4 2025 · Cash: $2.8BQ4 2025 · Debt: $430.1MQ1 2026 · Cash: $4.8BQ1 2026 · Debt: $430.9MQ2 2026 · Cash: $4.1BQ2 2026 · Debt: $431.6MQ3 2023Q2 2026
CashDebt
Profitability+100.0%Q2 2026
+15.6%+43.7%+71.9%+100.0%Q3 2023 · Gross margin: +100.0%Q4 2023 · Gross margin: +100.0%Q1 2024 · Gross margin: +100.0%Q2 2024 · Gross margin: +100.0%Q3 2024 · Gross margin: +100.0%Q4 2024 · Gross margin: +13.7%Q1 2025 · Gross margin: +25.8%Q2 2025 · Gross margin: +10.9%Q3 2025 · Gross margin: +13.4%Q4 2025 · Gross margin: +6.6%Q1 2026 · Gross margin: +30.5%Q2 2026 · Gross margin: +100.0%Q3 2023 · Operating margin: -4.5%Q4 2023 · Operating margin: -10.5%Q1 2024 · Operating margin: +8.3%Q2 2024 · Operating margin: +2.7%Q3 2024 · Operating margin: -2.2%Q4 2024 · Operating margin: -6.2%Q1 2025 · Operating margin: +9.8%Q2 2025 · Operating margin: -8.0%Q3 2025 · Operating margin: -4.3%Q4 2025 · Operating margin: -11.9%Q1 2026 · Operating margin: +15.2%Q2 2026 · Operating margin: +7.8%Q3 2023 · Net margin: -4.5%Q4 2023 · Net margin: -10.5%Q1 2024 · Net margin: +8.3%Q2 2024 · Net margin: +2.5%Q3 2024 · Net margin: -2.3%Q4 2024 · Net margin: -6.4%Q1 2025 · Net margin: +9.0%Q2 2025 · Net margin: -8.0%Q3 2025 · Net margin: -4.6%Q4 2025 · Net margin: -12.6%Q1 2026 · Net margin: +14.6%Q2 2026 · Net margin: +7.4%Q3 2023Q2 2026
Gross marginOperating marginNet margin
Revenue growth+70.4%Q2 2026
+17.6%+35.2%+52.8%+70.4%Q2 2024: +45.8%Q3 2024: +68.3%Q4 2024: +67.1%Q1 2025: +42.2%Q2 2025: +29.0%Q3 2025: +23.2%Q4 2025: +17.3%Q1 2026: +52.6%Q2 2026: +70.4%Q3 2023Q2 2026
Shares outstanding333.4MQ2 2026
83.4M166.7M250.1M333.4MQ3 2023: 223.1MQ4 2023: 227.1MQ1 2024: 293.8MQ2 2024: 304MQ3 2024: 243.1MQ4 2024: 265.9MQ1 2025: 305.9MQ2 2025: 270.2MQ3 2025: 259.3MQ4 2025: 283.2MQ1 2026: 329.8MQ2 2026: 333.4MQ3 2023Q2 2026
Valuation5.9Q2 2026
-13.9-3.86.416.5Q3 2023 · P/E: -4.8Q4 2023 · P/E: -3.5Q1 2024 · P/E: 4.8Q2 2024 · P/E: 16.5Q3 2024 · P/E: -24.1Q4 2024 · P/E: -5.4Q1 2025 · P/E: 3.0Q2 2025 · P/E: -6.0Q3 2025 · P/E: -8.9Q4 2025 · P/E: -2.9Q1 2026 · P/E: 1.3Q2 2026 · P/E: 5.9Q3 2023 · P/S: 0.9Q4 2023 · P/S: 1.5Q1 2024 · P/S: 1.6Q2 2024 · P/S: 1.7Q3 2024 · P/S: 2.1Q4 2024 · P/S: 1.4Q1 2025 · P/S: 1.1Q2 2025 · P/S: 1.9Q3 2025 · P/S: 1.6Q4 2025 · P/S: 1.5Q1 2026 · P/S: 0.7Q2 2026 · P/S: 1.8Q3 2023Q2 2026
P/EP/S
Revenue$11.7B2025
$2.9B$5.9B$8.8B$11.7B2019: $553.8M2020: $589.6M2021: $1.9B2022: $4.1B2023: $5.9B2024: $9.2B2025: $11.7B20192025
Net income-$443.2M2025
-$448.3M-$290.4M-$132.5M$25.4M2019: -$261.2M2020: -$406.8M2021: -$572.6M2022: -$606.3M2023: -$270.7M2024: $25.4M2025: -$443.2M20192025
EBITDA-$391.1M2025
-$406.8M-$241.4M-$76.1M$89.3M2019: -$252.5M2020: -$391M2021: -$551.3M2022: -$572.2M2023: -$212M2024: $89.3M2025: -$391.1M20192025
Free cash flow$1.1B2025
$41.3M$380.4M$719.4M$1.1B2019: -$191.4M2020: $208.7M2021: -$207.6M2022: $351.3M2023: -$297.7M2024: $950.3M2025: $1.1B20192025
EPS-$1.692025
-$2.37-$1.55-$0.73$0.12019: -$1.092020: -$1.72021: -$3.192022: -$2.852023: -$1.222024: $0.12025: -$1.6920192025
Cash / Debt$2.8B2025
$693.5M$1.4B$2.1B$2.8B2019 · Cash: $336.6M2019 · Debt: $02020 · Cash: $826.3M2020 · Debt: $142.5M2021 · Cash: $1.1B2021 · Debt: $02022 · Cash: $1.6B2022 · Debt: $298M2023 · Cash: $1.9B2023 · Debt: $298.8M2024 · Cash: $1.5B2024 · Debt: $299.6M2025 · Cash: $2.8B2025 · Debt: $430.1M20192025
CashDebt
Profitability+14.4%2025
-26.7%+15.5%+57.8%+100.0%2019 · Gross margin: +100.0%2020 · Gross margin: +100.0%2021 · Gross margin: +100.0%2022 · Gross margin: +100.0%2023 · Gross margin: +20.8%2024 · Gross margin: +20.1%2025 · Gross margin: +14.4%2019 · Operating margin: -46.8%2020 · Operating margin: -68.8%2021 · Operating margin: -29.7%2022 · Operating margin: -14.8%2023 · Operating margin: -4.0%2024 · Operating margin: +0.6%2025 · Operating margin: -3.4%2019 · Net margin: -47.2%2020 · Net margin: -69.0%2021 · Net margin: -29.8%2022 · Net margin: -14.7%2023 · Net margin: -4.6%2024 · Net margin: +0.3%2025 · Net margin: -3.8%20192025
Gross marginOperating marginNet margin
Revenue growth+27.5%2025
+56.4%+112.9%+169.3%+225.8%2020: +6.5%2021: +225.8%2022: +114.8%2023: +42.1%2024: +56.5%2025: +27.5%20192025
Shares outstanding262.4M2025
66.5M132.9M199.4M265.9M2019: 239.3M2020: 239.3M2021: 179M2022: 212.5M2023: 221.7M2024: 265.9M2025: 262.4M20192025
Valuation-8.52025
15.250.986.5122.22019 · P/E: -3.92020 · P/E: -20.52021 · P/E: -2.52022 · P/E: -0.92023 · P/E: -7.52024 · P/E: 122.22025 · P/E: -8.52019 · P/S: 1.82020 · P/S: 14.12021 · P/S: 0.72022 · P/S: 0.12023 · P/S: 0.32024 · P/S: 0.42025 · P/S: 0.320192025
P/EP/S

Next catalyst

Catalysts

Earnings
2026-11-09
Revenue est. $4.7B · Updated 1h ago

No unusual perp activity right now.

Research data

Analysts, filings and peer context

Estimates

6
DateEPS estimateRevenue estimateGrowthAnalysts
FY 20261.91$18.7B+59%6
FY 20272.35$20.8B+78%6
FY 20282.77$24.2B+107%6
FY 20293.74$30.9B+164%3
FY 20303.94$32.5B+177%2
Q1 20272.36$5.3B+14%1

Company events

6
2026-11-09EarningsActual - / Estimate -0.14-
2026-08-06Earnings · Before market openActual 1.1 / Estimate 0.4Beat
2026-05-06EarningsActual 2.07 / Estimate 1.21Beat
2026-02-10EarningsActual -1.24 / Estimate -0.92Miss
2025-11-06EarningsActual -0.53 / Estimate -0.55Beat
2025-08-06EarningsActual -0.89 / Estimate -0.9Beat

Peer comparison

Similar listed perps

FMP company data

Company intelligence

Updated: Sep 18, 2026, 05:53 AM UTC

Company profile

Sector
Healthcare
Industry
Medical - Healthcare Plans
Chief executive
Mark Thomas Bertolini
Employees
2,305
IPO date
Mar 3, 2021
Country
US
Exchange
New York Stock Exchange
Website
Altman Z-scorei1.9
Piotroski scorei6/9
FMP ratingiA-
Owner earningsi$2.06B$6.17 per share
ESG risk ratingiB-Industry rank: 13 out of 15

Rating factors

Return on equityi
5
Return on assetsi
4
Debt to equityi
3
Price to earningsi
2
Price to booki
2
Market cap history
$9.87B+17.1%Jun 26 – Sep 26
$8.36B$9.29B$10.22BHigh: $10.22B · 2026-09-14Low: $8.36B · 2026-08-10Latest: $9.87B · 2026-09-17Jun 26Jul 26Aug 26Sep 26
Latest: $9.87B · 2026-09-17High: $10.22B · 2026-09-14Low: $8.36B · 2026-08-10
Largest fund holders
FundWeightShares held
VTI0.01%7.6M
IWM0.26%6.4M
AVUV0.62%5.9M
VB0.09%5.5M
NJM0.12%4.8M
VBK0.21%3.2M
VXF0.08%2.6M
FSSNX0.21%2.3M
IWO0.52%2.3M
NLO0.23%1.7M
FESM0.76%1.5M
FCAGX0.51%1.5M

Analyst track record

How the analysts covering OSCR have done: ratings, price-target accuracy and the measured reaction after their calls.

12 months3 years
Ratings44105
Analysts1517
Buy / hold / sell10 / 23 / 1136 / 39 / 30
Upgrades / downgrades / initiations7 / 0 / 38 / 8 / 8
Price targets hit / missed30 / 12 (71%)89 / 12 (88%)
Avg. return after a rating (TipRanks)+52.1%+80.4%
Best / worst call+171.8% / -39.0%+273.8% / -39.0%

After buy calls on this stock: median 21-day move -0.5% vs S&P 500 -1.3% (n = 31)

Most accurate on this stock

Share of an analyst's price targets on this stock that the price reached within 12 months (our measurement over the last 3 years, at least 8 targets). It describes past calls, not the odds of the current one.

  1. Adam RonBank of America Securities88% hit rate on this stock · 8 targets measuredSelltarget $25.00Aug 6, 2026
  2. Stephen BaxterWells Fargo43% hit rate on this stock · 14 targets measuredHoldtarget $27.00Sep 15, 2026

Latest ratings

DateAnalystCallTarget
Sep 23, 2026Jessica TassanPiper SandlerBuyMaintained$48.00
Sep 22, 2026Parker SnureRaymond JamesBuyMaintained–
Sep 22, 2026Parker SnureRaymond JamesBuyMaintained–
Sep 18, 2026Parker SnureRaymond JamesBuyMaintained$42.00
Sep 17, 2026Jessica TassanPiper SandlerBuyReiterated$48.00
Consensus over the last 12 months buy hold sell avg. target month-end close
Monthly buy, hold and sell shares of analyst ratings with the average price target and the month-end close$10.00$15.00$20.00$25.00$30.00Nov 25 · Buy 1 · Hold 3 · Sell 5Nov 25Dec 25 · Buy 1 · Hold 3 · Sell 5Jan 26 · Buy 1 · Hold 5 · Sell 3Jan 26Feb 26 · Buy 2 · Hold 4 · Sell 3Mar 26 · Buy 2 · Hold 4 · Sell 3Mar 26Apr 26 · Buy 2 · Hold 5 · Sell 2May 26 · Buy 1 · Hold 7 · Sell 2May 26Jun 26 · Buy 2 · Hold 7 · Sell 1Jul 26 · Buy 3 · Hold 7 · Sell 1Jul 26Aug 26 · Buy 2 · Hold 7 · Sell 2Sep 26 · Buy 3 · Hold 7 · Sell 3Sep 26Oct 26 · Buy 3 · Hold 7 · Sell 3Nov 25 · avg. target $14.18Dec 25 · avg. target $15.04Jan 26 · avg. target $16.29Feb 26 · avg. target $16.00Mar 26 · avg. target $16.00Apr 26 · avg. target $16.44May 26 · avg. target $17.44Jun 26 · avg. target $20.00Jul 26 · avg. target $21.60Aug 26 · avg. target $26.50Sep 26 · avg. target $31.82Oct 26 · avg. target $31.82Nov 25 · month-end close $17.97Dec 25 · month-end close $14.37Jan 26 · month-end close $14.35Feb 26 · month-end close $13.64Mar 26 · month-end close $11.47Apr 26 · month-end close $18.46May 26 · month-end close $22.23Jun 26 · month-end close $28.52Jul 26 · month-end close $31.22Aug 26 · month-end close $29.96Sep 26 · month-end close $30.84Oct 26 · month-end close $30.94

Share of analysts per call each month (latest call per analyst within 180 days). Targets and closes in USD.

TipRanks data via FMP · computed Oct 2, 2026 · 44 ratings

Frequently asked questions

Where can I trade OSCR perpetual futures?

Oscar Health, Inc. (OSCR) perpetual futures trade on 3 crypto venues, including BingX, LBank, OKX. PerpEquities compares them by live price, funding rate, open interest and liquidity.

Can I trade OSCR around the clock?

Yes. Unlike the underlying stock, OSCR perpetuals trade 24/7 — including weekends and outside regular market hours.

What is the funding rate on OSCR perpetuals?

Right now the OSCR perp funding rate is 0.0% annualized (venue median), ranging from 0.0% to +5.5% across 3 venues. A positive rate means longs pay shorts. PerpEquities shows the live rate and its history for every venue.

How does the OSCR perp price compare to the Oscar Health, Inc. stock?

The venue-median OSCR perp mark is $32.5 versus a reference stock price of $32.5, a basis of 0.0%. Perps follow the stock through an index price; the gap widens when funding or liquidity diverge between venues.

What is a OSCR perpetual future?

A OSCR perpetual is a derivative that tracks the price of Oscar Health, Inc. with no expiry date. It lets you take long or short exposure to Oscar Health, Inc. on crypto venues, around the clock.

What is OSCRUSDT perpetual?

OSCRUSDT is the symbol most crypto exchanges use for the Oscar Health, Inc. perpetual settled in USDT (Tether). It tracks the OSCR share price through an index, trades 24/7 with leverage and never expires.

Embed this asset

OSCR perpetuals · perpequities.comOSCR perpetuals · perpequities.com
<a href="https://perpequities.com/stocks/oscr-perp"><img src="https://perpequities.com/badge/oscr-perp.svg" width="240" height="64" alt="OSCR perpetuals · perpequities.com" loading="lazy"></a>

Next step

Stay on top of OSCR perps

Signals with a track record

Analysts who hit 70%+ of their targets on the perps we track, congress buys over $500k, 13F positions over $5M, funding spreads that have paid for days. Every post shows the evidence. Free, no sign-up.

Join on Telegram

Weekly digest by email

The listings, funding and moves that matter for OSCR — one email every Sunday.

Watchlist and alerts

Price and funding alerts for OSCR, via push or Telegram.

Set an alert

Follow the live feed

Daily movers, new listings and funding extremes as they happen.

Follow on X